IFG Advisory LLC Acquires New Position in Bristol Myers Squibb Company $BMY

Key Points

• IFG Advisory LLC disclosed a new Q3 position in Bristol Myers Squibb of 51,811 shares, valued at about $2.34 million.
• BMY missed Q4 EPS ($1.26 vs. $1.65 expected) and set FY‑2026 guidance of $6.05–$6.35, which weighed on the stock; analysts’ consensus rating is a Hold with a $60.71 price target.
• Pipeline and commercial positives include a positive Phase 2 Reblozyl readout in alpha‑thalassemia and roughly $2.3B in annualized Reblozyl sales, supported by an AI collaboration to accelerate trials.

IFG Advisory LLC acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,811 shares of the biopharmaceutical company's stock, valued at approximately $2,337,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its holdings in Bristol Myers Squibb by 11.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock worth $818,105,000 after buying an additional 1,873,618 shares during the period. Claro Advisors LLC lifted its position in shares of Bristol Myers Squibb by 2.4% during the third quarter. Claro Advisors LLC now owns 16,543 shares of the biopharmaceutical company's stock worth $746,000 after acquiring an additional 384 shares in the last quarter. Level Four Advisory Services LLC boosted its holdings in shares of Bristol Myers Squibb by 4.0% in the third quarter. Level Four Advisory Services LLC now owns 25,055 shares of the biopharmaceutical company's stock worth $1,130,000 after acquiring an additional 968 shares during the period. Teachers Retirement System of The State of Kentucky raised its stake in shares of Bristol Myers Squibb by 76.2% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 484,912 shares of the biopharmaceutical company's stock valued at $21,869,000 after purchasing an additional 209,700 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in Bristol Myers Squibb by 24.0% during the 3rd quarter. Victory Capital Management Inc. now owns 4,059,651 shares of the biopharmaceutical company's stock worth $183,090,000 after purchasing an additional 784,566 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BMY shares. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Citigroup upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "neutral" rating in a report on Friday, February 6th. Bank of America upgraded shares of Bristol Myers Squibb from a "neutral" rating to a "buy" rating and increased their target price for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 3rd. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 8th. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Hold" and a consensus price target of $60.71.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Top-line Phase 2 results for Reblozyl in alpha‑thalassemia came back positive (primary and key secondary endpoints met; safety consistent with prior data), which strengthens BMY's late‑stage pipeline optionality and potential label expansion. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Positive Sentiment: Commercial momentum: Reblozyl has topped roughly $2.3B in annualized sales and company commentary plus an AI collaboration (Evinova) to speed trial execution underline both near‑term revenue support and improved R&D efficiency. These items support BMY’s top‑line outlook if label/drug expansion continues. Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? Bristol Myers Squibb Adds Reblozyl Data And AI To Pipeline Story
• Neutral Sentiment: Round‑up/earnings coverage: BMY appears in lists of Q4 “outperformers” for branded pharma on revenue strength, but underlying EPS dynamics were mixed—investors should read the details rather than rely on headlines. Q4 Earnings Outperformers: Bristol-Myers Squibb NYSE: BMY And The Rest Of The Branded Pharmaceuticals Stocks
• Neutral Sentiment: Industry context: Strength at peers (e.g., Merck’s Keytruda momentum) highlights competitive dynamics in oncology that influence investor expectations for BMY’s oncology franchises. Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
• Neutral Sentiment: Macro/sector themes such as nanomedicine and dividend‑income positioning appeared in recent coverage; these are background drivers but less directly tied to BMY’s immediate price move. Global Nanomedicine Market is Projected Cross
• Negative Sentiment: Market reaction and fundamentals: several news pieces note BMY’s intraday/close decline (broader selling). The core negative catalysts are the Q4 EPS miss (reported EPS below consensus) and FY‑2026 guidance that sits below some analyst forecasts — these credit‑and‑earnings concerns explain why the stock is down despite pipeline positives. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $60.69 on Friday. The company's fifty day moving average price is $57.55 and its 200-day moving average price is $50.91. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market capitalization of $123.59 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 0.18 and a beta of 0.26. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analysts' expectations of $12.24 billion. During the same quarter last year, the firm posted $1.67 earnings per share. The firm's revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. Bristol Myers Squibb's payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.